Sybil Health — Precision Hormonal Intelligence
Key Traction Highlights
Key Traction Highlights
Key Traction Highlights
- Clinical Decision Support(CDS) AI internally launched (Dec 2025)
- CDS: 2 clinical pilots underway (LOIs signed)
- Precision phenotyping model validated on longitudinal datasets
- National telehealth launched Q4 2025
“Why Now”
Key Traction Highlights
Key Traction Highlights
The women's hormonal market (US) is an $186B+ opportunity with massive unmet need.
Only 7% of OB-GYNs are trained in menopause care — yet demand is exploding.
AI + clinical support tools will define the next decade of women’s health.
What We Are Raising / What We Need
What We Are Raising / What We Need
What We Are Raising / What We Need
- Looking for: early “friends of the round” investors
- Use of funds: clinical validation, regulatory alignment, and AI scaling
- Stage: post-MVP, pilot-ready, strong founder-market fit
Meet the Founder
What We Are Raising / What We Need
What We Are Raising / What We Need
Olga Grygoryan, MBA:
- 18+ years in biotech & medtech (J&J, Amgen, Medtronic), AI/ML program leadership, FDA-regulated product delivery.
- Founder of Sybil Health.
Email: wecare@sybil.health